Michael S Middleton1, Mark L Van Natta2, Elhamy R Heba1, Adina Alazraki3, Andrew T Trout4, Prakash Masand5, Elizabeth M Brunt6, David E Kleiner7, Edward Doo8, James Tonascia2, Joel E Lavine9, Wei Shen9, Gavin Hamilton1, Jeffrey B Schwimmer10, Claude B Sirlin1. 1. Liver Imaging Group, Department of Radiology, UCSD School of Medicine, San Diego, CA. 2. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Emory University School of Medicine, Department of Radiology and Imaging Sciences, Atlanta, GA. 4. Cincinnati Children's Hospital, Department of Radiology, Cincinnati, OH. 5. Texas Children's Hospital, Houston, TX. 6. Emeritus, Washington University School of Medicine, St. Louis, MO. 7. Laboratory of Pathology, National Cancer Institute, Bethesda, MD. 8. Liver Diseases Section, Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 9. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Columbia University Medical Center, New York, NY. 10. Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California; and Department of Gastroenterology, Rady Children's Hospital, San Diego, CA.
Abstract
We assessed the performance of magnetic resonance imaging (MRI) proton density fat fraction (PDFF) in children to stratify hepatic steatosis grade before and after treatment in the Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease in Children (CyNCh) trial, using centrally scored histology as reference. Participants had multiecho 1.5 Tesla (T) or 3T MRI on scanners from three manufacturers. Of 169 enrolled children, 110 (65%) and 83 (49%) had MRI and liver biopsy at baseline and at end of treatment (EOT; 52 weeks), respectively. At baseline, 17% (19 of 110), 28% (31 of 110), and 55% (60 of 110) of liver biopsies showed grades 1, 2, and 3 histological steatosis; corresponding PDFF (mean ± SD) values were 10.9 ± 4.1%, 18.4 ± 6.2%, and 25.7 ± 9.7%, respectively. PDFF classified grade 1 versus 2-3 and 1-2 versus 3 steatosis with areas under receiving operator characteristic curves (AUROCs) of 0.87 (95% confidence interval [CI], 0.80, 0.94) and 0.79 (0.70, 0.87), respectively. PDFF cutoffs at 90% specificity were 17.5% for grades 2-3 steatosis and 23.3% for grade 3 steatosis. At EOT, 47% (39 of 83), 41% (34 of 83), and 12% (10 of 83) of biopsies showed improved, unchanged, and worsened steatosis grade, respectively, with corresponding PDFF (mean ± SD) changes of -7.8 ± 6.3%, -1.2 ± 7.8%, and 4.9 ± 5.0%, respectively. PDFF change classified steatosis grade improvement and worsening with AUROCs (95% CIs) of 0.76 (0.66, 0.87) and 0.83 (0.73, 0.92), respectively. PDFF change cut-off values at 90% specificity were -11.0% and +5.5% for improvement and worsening. CONCLUSION: MRI-estimated PDFF has high diagnostic accuracy to both classify and predict histological steatosis grade and change in histological steatosis grade in children with NAFLD. (Hepatology 2018;67:858-872).
RCT Entities:
We assessed the performance of magnetic resonance imaging (MRI) proton density fat fraction (PDFF) in children to stratify hepatic steatosis grade before and after treatment in the Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease in Children (CyNCh) trial, using centrally scored histology as reference. Participants had multiecho 1.5 Tesla (T) or 3T MRI on scanners from three manufacturers. Of 169 enrolled children, 110 (65%) and 83 (49%) had MRI and liver biopsy at baseline and at end of treatment (EOT; 52 weeks), respectively. At baseline, 17% (19 of 110), 28% (31 of 110), and 55% (60 of 110) of liver biopsies showed grades 1, 2, and 3 histological steatosis; corresponding PDFF (mean ± SD) values were 10.9 ± 4.1%, 18.4 ± 6.2%, and 25.7 ± 9.7%, respectively. PDFF classified grade 1 versus 2-3 and 1-2 versus 3 steatosis with areas under receiving operator characteristic curves (AUROCs) of 0.87 (95% confidence interval [CI], 0.80, 0.94) and 0.79 (0.70, 0.87), respectively. PDFF cutoffs at 90% specificity were 17.5% for grades 2-3 steatosis and 23.3% for grade 3 steatosis. At EOT, 47% (39 of 83), 41% (34 of 83), and 12% (10 of 83) of biopsies showed improved, unchanged, and worsened steatosis grade, respectively, with corresponding PDFF (mean ± SD) changes of -7.8 ± 6.3%, -1.2 ± 7.8%, and 4.9 ± 5.0%, respectively. PDFF change classified steatosis grade improvement and worsening with AUROCs (95% CIs) of 0.76 (0.66, 0.87) and 0.83 (0.73, 0.92), respectively. PDFF change cut-off values at 90% specificity were -11.0% and +5.5% for improvement and worsening. CONCLUSION: MRI-estimated PDFF has high diagnostic accuracy to both classify and predict histological steatosis grade and change in histological steatosis grade in children with NAFLD. (Hepatology 2018;67:858-872).
Authors: Mark Bydder; Takeshi Yokoo; Gavin Hamilton; Michael S Middleton; Alyssa D Chavez; Jeffrey B Schwimmer; Joel E Lavine; Claude B Sirlin Journal: Magn Reson Imaging Date: 2008-02-21 Impact factor: 2.546
Authors: Michael S Middleton; William Haufe; Jonathan Hooker; Magnus Borga; Olof Dahlqvist Leinhard; Thobias Romu; Patrik Tunón; Gavin Hamilton; Tanya Wolfson; Anthony Gamst; Rohit Loomba; Claude B Sirlin Journal: Radiology Date: 2017-03-09 Impact factor: 11.105
Authors: Geraldine H Kang; Irene Cruite; Masoud Shiehmorteza; Tanya Wolfson; Anthony C Gamst; Gavin Hamilton; Mark Bydder; Michael S Middleton; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2011-07-18 Impact factor: 4.813
Authors: Priscila L Sanches; Aline de Piano; Raquel M S Campos; June Carnier; Marco T de Mello; Natália Elias; Francisco A H Fonseca; Deborah C L Masquio; Patrícia L da Silva; Flavia C Corgosinho; Lian Tock; Lila M Oyama; Sergio Tufik; Ana R Dâmaso Journal: J Clin Lipidol Date: 2014-03-02 Impact factor: 4.766
Authors: Emil Achmad; Takeshi Yokoo; Gavin Hamilton; Elhamy R Heba; Jonathan C Hooker; Christopher Changchien; Michael Schroeder; Tanya Wolfson; Anthony Gamst; Jeffrey B Schwimmer; Joel E Lavine; Claude B Sirlin; Michael S Middleton Journal: Abdom Imaging Date: 2015-10
Authors: Takeshi Yokoo; Julie M Collins; Robert F Hanna; Mark Bydder; Michael S Middleton; Claude B Sirlin Journal: J Magn Reson Imaging Date: 2008-07 Impact factor: 4.813
Authors: Elizabeth L Yu; Shahrokh Golshan; Kathryn E Harlow; Jorge E Angeles; Janis Durelle; Nidhi P Goyal; Kimberly P Newton; Mary Catherine Sawh; Jonathan Hooker; Ethan Z Sy; Michael S Middleton; Claude B Sirlin; Jeffrey B Schwimmer Journal: J Pediatr Date: 2018-12-14 Impact factor: 4.406
Authors: Nidhi P Goyal; Mary Catherine Sawh; Patricia Ugalde-Nicalo; Jorge E Angeles; James A Proudfoot; Kimberly P Newton; Michael S Middleton; Claude B Sirlin; Jeffrey B Schwimmer Journal: J Pediatr Gastroenterol Nutr Date: 2020-01 Impact factor: 2.839
Authors: Adrija Mamidipalli; Kathryn J Fowler; Gavin Hamilton; Tanya Wolfson; Yesenia Covarrubias; Calvin Tran; Soudabeh Fazeli; Curtis N Wiens; Alan McMillan; Nathan S Artz; Luke M Funk; Guilherme M Campos; Jacob A Greenberg; Anthony Gamst; Michael S Middleton; Jeffrey B Schwimmer; Scott B Reeder; Claude B Sirlin Journal: Eur Radiol Date: 2020-04-21 Impact factor: 5.315
Authors: Jonathan C Hooker; Gavin Hamilton; Charlie C Park; Steven Liao; Tanya Wolfson; Soudabeh Fazeli Dehkordy; Cheng William Hong; Adrija Mamidipalli; Anthony Gamst; Rohit Loomba; Claude B Sirlin Journal: Abdom Radiol (NY) Date: 2019-02
Authors: Jeffrey B Schwimmer; Patricia Ugalde-Nicalo; Jean A Welsh; Jorge E Angeles; Maria Cordero; Kathryn E Harlow; Adina Alazraki; Janis Durelle; Jack Knight-Scott; Kimberly P Newton; Rebecca Cleeton; Cynthia Knott; Juna Konomi; Michael S Middleton; Curtis Travers; Claude B Sirlin; Albert Hernandez; Ahlia Sekkarie; Courtney McCracken; Miriam B Vos Journal: JAMA Date: 2019-01-22 Impact factor: 56.272